{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:14Z","timestamp":1792521614009,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR230020"],"award-info":[{"award-number":["RR230020"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01LM011934"],"award-info":[{"award-number":["R01LM011934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["R01HG012748"],"award-info":[{"award-number":["R01HG012748"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Aging","award":["R01AG072799"],"award-info":[{"award-number":["R01AG072799"]}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["OT2OD038051"],"award-info":[{"award-number":["OT2OD038051"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R24HL180372"],"award-info":[{"award-number":["R24HL180372"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD008720"],"award-info":[{"award-number":["U01FD008720"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02423-7","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:43:48Z","timestamp":1784875428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status of anti-obesity medications and performance, an EHR based survey"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoyang","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2423_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","volume":"384","author":"M Ng","year":"2014","unstructured":"Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766\u201381.","journal-title":"Lancet"},{"key":"2423_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.psc.2011.08.005","volume":"34","author":"NS Mitchell","year":"2011","unstructured":"Mitchell NS, Catenacci VA, Wyatt HR, Hill JO. Obesity: overview of an epidemic. Psychiatr Clin North Am. 2011;34:717\u201332.","journal-title":"Psychiatr Clin North Am"},{"key":"2423_CR3","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1038\/oby.2008.351","volume":"16","author":"Y Wang","year":"2008","unstructured":"Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. Obesity. 2008;16:2323\u201330.","journal-title":"Obesity"},{"key":"2423_CR4","unstructured":"Obesity Epidemiology. Oxford University Press; 2008."},{"key":"2423_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jval.2016.02.008","volume":"19","author":"DD Kim","year":"2016","unstructured":"Kim DD, Basu A. Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. Value Health. 2016;19:602\u201313.","journal-title":"Value Health"},{"key":"2423_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamasurg.2017.5025","volume":"153","author":"AP Courcoulas","year":"2018","unstructured":"Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. JAMA Surg. 2018;153:427\u201334.","journal-title":"JAMA Surg"},{"key":"2423_CR7","doi-asserted-by":"publisher","first-page":"e046407","DOI":"10.1136\/bmjopen-2020-046407","volume":"11","author":"M Brissman","year":"2021","unstructured":"Brissman M, Beamish AJ, Olbers T, Marcus C. Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. BMJ Open. 2021;11:e046407.","journal-title":"BMJ Open"},{"key":"2423_CR8","doi-asserted-by":"crossref","unstructured":"Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023;58.","DOI":"10.1016\/j.eclinm.2023.101882"},{"key":"2423_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care"},{"key":"2423_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341\u201352.","journal-title":"Lancet"},{"key":"2423_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201\u201323.","journal-title":"Nat Rev Drug Discov"},{"key":"2423_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"2423_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205\u201316.","journal-title":"N Engl J Med"},{"key":"2423_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cpp.1942","volume":"23","author":"TA Carey","year":"2016","unstructured":"Carey TA, Stiles WB. Some Problems with Randomized Controlled Trials and Some Viable Alternatives. Clin Psychol Psychother. 2016;23:87\u201395.","journal-title":"Clin Psychol Psychother"},{"key":"2423_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41366-021-01019-6","volume":"46","author":"G Calderon","year":"2022","unstructured":"Calderon G, Gonzalez-Izundegui D, Shan KL, Garcia-Valencia OA, Cifuentes L, Campos A, et al. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes. 2022;46:555\u201363.","journal-title":"Int J Obes"},{"key":"2423_CR16","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/oby.24331","volume":"33","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan H, Butsch WS, Schulte R, Casacchia NJ, Le P, Boyer CB, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obes (Silver Spring). 2025;33:1657\u201367.","journal-title":"Obes (Silver Spring)"},{"key":"2423_CR17","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/oby.24169","volume":"32","author":"JD Ard","year":"2024","unstructured":"Ard JD, Hong Y-R, Foster GD, Medcalf A, Nadolsky S, Cardel MI. Twelve-month analysis of real-world evidence from a telehealth obesity-treatment provider using antiobesity medications. Obes (Silver Spring). 2024;32:2246\u201354.","journal-title":"Obes (Silver Spring)"},{"key":"2423_CR18","doi-asserted-by":"publisher","first-page":"102777","DOI":"10.1016\/j.eclinm.2024.102777","volume":"75","author":"M Anson","year":"2024","unstructured":"Anson M, Henney AE, Broadwell N, Zhao SS, Ibarburu GH, Lip GYH, et al. Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. EClinicalMedicine. 2024;75:102777.","journal-title":"EClinicalMedicine"},{"key":"2423_CR19","first-page":"574","volume":"216","author":"G Hripcsak","year":"2015","unstructured":"Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inf. 2015;216:574\u20138.","journal-title":"Stud Health Technol Inf"},{"key":"2423_CR20","first-page":"1156","volume":"2006","author":"K Zeng","year":"2006","unstructured":"Zeng K, Bodenreider O, Kilbourne J, Nelson S. RxNav: a web service for standard drug information. AMIA Annu Symp Proc. 2006;2006:1156.","journal-title":"AMIA Annu Symp Proc"},{"key":"2423_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jamia\/ocad247","volume":"31","author":"C Reich","year":"2024","unstructured":"Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al. OHDSI Standardized Vocabularies\u2014a large-scale centralized reference ontology for international data harmonization. J Am Med Inf Assoc. 2024;31:583\u201390.","journal-title":"J Am Med Inf Assoc"},{"key":"2423_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. Obesity. 2019;27:591\u2013602.","journal-title":"Obesity"},{"key":"2423_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12874-024-02177-7","volume":"24","author":"LR Kalankesh","year":"2024","unstructured":"Kalankesh LR, Monaghesh E. Utilization of EHRs for clinical trials: a systematic review. BMC Med Res Methodol. 2024;24:70.","journal-title":"BMC Med Res Methodol"},{"key":"2423_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1136\/ard-2022-222626","volume":"82","author":"R Knevel","year":"2023","unstructured":"Knevel R, Liao KP. From real-world electronic health record data to real-world results using artificial intelligence. Ann Rheum Dis. 2023;82:306\u201311.","journal-title":"Ann Rheum Dis"},{"key":"2423_CR25","doi-asserted-by":"publisher","unstructured":"Strayer N, Vessels T, Choi K, Zhang S, Li Y, Han L, et al. Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.03.28.24305045.","DOI":"10.1101\/2024.03.28.24305045"},{"key":"2423_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"2423_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155\u20139.","journal-title":"Oman Med J"},{"key":"2423_CR28","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.23083","author":"H Kan","year":"2023","unstructured":"Kan H, Bae JP, Dunn JP, Buysman EK, Gronroos NN, Swindle JP, et al. Real-world primary nonadherence to antiobesity medications. J Managed Care Specialty Pharm. 2023. https:\/\/doi.org\/10.18553\/jmcp.2023.23083.","journal-title":"J Managed Care Specialty Pharm"},{"key":"2423_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.23952","volume":"32","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. Early- and later-stage persistence with antiobesity medications: A retrospective cohort study. Obesity. 2024;32:486\u201393.","journal-title":"Obesity"},{"key":"2423_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7570\/jomes22029","volume":"31","author":"H-J Ko","year":"2022","unstructured":"Ko H-J, Kim J-W, Lim S. Adherence to and Dropout from Liraglutide 3.0\u00a0mg Obesity Treatment in a Real-World Setting. J Obes Metab Syndr. 2022;31:254\u201362.","journal-title":"J Obes Metab Syndr"},{"key":"2423_CR31","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.7.740","author":"N Kim","year":"2022","unstructured":"Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, et al. Cost-effectiveness analysis of semaglutide 2.4\u00a0mg for the treatment of adult patients with overweight and obesity in the United States. J Managed Care Specialty Pharm. 2022. https:\/\/doi.org\/10.18553\/jmcp.2022.28.7.740.","journal-title":"J Managed Care Specialty Pharm"},{"key":"2423_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/dom.12275","volume":"16","author":"JH Shin","year":"2014","unstructured":"Shin JH, Gadde KM, \u00d8stbye T, Bray GA. Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment. Diabetes Obes Metab. 2014;16:766\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"2423_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40263-015-0229-z","volume":"29","author":"A Verrotti","year":"2015","unstructured":"Verrotti A, Parisi P, Agostinelli S, Loiacono G, Marra F, Coppola G, et al. Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study. CNS Drugs. 2015;29:163\u20139.","journal-title":"CNS Drugs"},{"key":"2423_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin W-Y, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38\u201348.","journal-title":"JAMA"},{"key":"2423_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"2423_CR36","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/oby.22727","volume":"28","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Mechanick JI. Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity. Obesity. 2020;28:484\u201392.","journal-title":"Obesity"},{"key":"2423_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ijo.2009.2","volume":"33","author":"AM Sharma","year":"2009","unstructured":"Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33:289\u201395.","journal-title":"Int J Obes"},{"key":"2423_CR38","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/oby.23120","volume":"29","author":"A Acosta","year":"2021","unstructured":"Acosta A, Camilleri M, Abu Dayyeh B, Calderon G, Gonzalez D, McRae A, et al. Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Obesity. 2021;29:662\u201371.","journal-title":"Obesity"},{"key":"2423_CR39","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.3390\/ijms23073451","volume":"23","author":"J Klen","year":"2022","unstructured":"Klen J, Dol\u017ean V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus and obesity: The impact of pharmacological properties and genetic factors. Int J Mol Sci. 2022;23:3451.","journal-title":"Int J Mol Sci"},{"key":"2423_CR40","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/oby.24300","volume":"33","author":"A Phan","year":"2025","unstructured":"Phan A, Carette C, Narjoz C, Rives-Lange C, Rassy N, Czernichow S, et al. A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity. Obes (Silver Spring). 2025;33:1237\u201342.","journal-title":"Obes (Silver Spring)"},{"key":"2423_CR41","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41586-026-10330-z","volume":"653","author":"QJ Su","year":"2026","unstructured":"Su QJ, Ashenhurst JR, Xu W, Tran V, Ryanne Wu R, Weldon CH, et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026;653:770\u20135.","journal-title":"Nature"},{"key":"2423_CR42","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11154-023-09804-6","volume":"24","author":"K Trang","year":"2023","unstructured":"Trang K, Grant SFA. Genetics and epigenetics in the obesity phenotyping scenario. Rev Endocr Metab Disord. 2023;24:775\u201393.","journal-title":"Rev Endocr Metab Disord"},{"key":"2423_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11154-023-09813-5","volume":"24","author":"A Preda","year":"2023","unstructured":"Preda A, Carbone F, Tirandi A, Montecucco F, Liberale L. Obesity phenotypes and cardiovascular risk: From pathophysiology to clinical management. Rev Endocr Metab Disord. 2023;24:901\u201319.","journal-title":"Rev Endocr Metab Disord"},{"key":"2423_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-023-09829-x","volume":"24","author":"P Portincasa","year":"2023","unstructured":"Portincasa P, Fr\u00fchbeck G. Phenotyping the obesities: reality or utopia? Rev Endocr Metab Disord. 2023;24:767\u201373.","journal-title":"Rev Endocr Metab Disord"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02423-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:02:08Z","timestamp":1792519328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02423-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2423"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02423-7","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Texas Institutional Review Board (IRB) approved the study in accordance with the Declaration of Helsinki, and the Ethics Committee waived the need for written informed consent from participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}